Atkinson Meredith A, Kim Ji Young, Roy Cindy N, Warady Bradley A, White Colin T, Furth Susan L
Division of Pediatric Nephrology, Johns Hopkins University School of Medicine, 200 N. Wolfe Street, Baltimore, MD, 21287, USA,
Pediatr Nephrol. 2015 Apr;30(4):635-43. doi: 10.1007/s00467-014-2991-4. Epub 2014 Nov 8.
Hepcidin, a key iron regulatory protein, is elevated in patients with chronic kidney disease (CKD). Its role in the development and progression of the anemia of CKD in children remains poorly defined.
Cross-sectional and longitudinal study in children aged 1-16 years with stage 2-4 CKD in the Chronic Kidney Disease in Children (CKiD) cohort (n = 133) with hepcidin measured at baseline and hemoglobin (HGB) measured annually at follow-up. Anemia was defined as HGB <5th percentile for age/sex OR treatment with an erythropoiesis-stimulating agent (ESA).
Hepcidin levels correlated negatively with glomerular filtration rate (GFR; r = -0.22, p = 0.01) and positively with ferritin (r = 0.67, p < 0.001). At the lower end of the GFR spectrum at baseline (10th percentile, 27.5 mL/min/1.73 m(2)), higher hepcidin was associated with a 0.87 g/dL decrease in HGB during follow-up (95 % CI -1.69, -0.05 g/dL, p = 0.038). At higher GFR percentiles there was no significant association between baseline hepcidin and HGB during follow-up. Among 90 non-anemic subjects at baseline, 23.3 % developed incident anemia. In subjects with GFR ≤ the median, a higher hepcidin level was associated with an increased risk of incident anemia (at the 10th percentile GFR, HR 3.471, 95 % CI 1.228, 9.810, p = 0.019; at the 25th percentile GFR, HR 2.641, 95 % CI 1.213, 5.750, p = 0.014; at the 50th percentile GFR, HR 1.953, 95 % CI 1.011, 3.772, p = 0.046). Among subjects with GFR at the 75th percentile or above, incrementally higher baseline hepcidin was not associated with increased anemia risk.
Higher hepcidin levels are associated with a decreased HGB and an increased risk of incident anemia, and this association is most significant among subjects with lower GFR.
铁调素是一种关键的铁调节蛋白,在慢性肾脏病(CKD)患者中水平升高。其在儿童CKD贫血发生和发展中的作用仍不清楚。
对儿童慢性肾脏病(CKiD)队列中1 - 16岁的2 - 4期CKD儿童进行横断面和纵向研究(n = 133),在基线时测量铁调素,随访期间每年测量血红蛋白(HGB)。贫血定义为HGB低于年龄/性别的第5百分位数或接受促红细胞生成素(ESA)治疗。
铁调素水平与肾小球滤过率(GFR)呈负相关(r = -0.22,p = 0.01),与铁蛋白呈正相关(r = 0.67,p < 0.001)。在基线GFR范围的下限(第10百分位数,27.5 mL/min/1.73 m²),较高的铁调素与随访期间HGB降低0.87 g/dL相关(95% CI -1.69,-0.05 g/dL,p = 0.038)。在较高的GFR百分位数时,基线铁调素与随访期间的HGB之间无显著关联。在基线时90名非贫血受试者中,23.3%发生了新发贫血。在GFR≤中位数的受试者中,较高的铁调素水平与新发贫血风险增加相关(在GFR第10百分位数时,HR 3.471,95% CI 1.228,9.810,p = 0.019;在GFR第25百分位数时,HR 2.641,95% CI 1.213,5.750,p = 0.014;在GFR第50百分位数时,HR 1.953,95% CI 1.011,3.772,p = 0.046)。在GFR处于第75百分位数或以上的受试者中,基线铁调素逐渐升高与贫血风险增加无关。
较高的铁调素水平与HGB降低和新发贫血风险增加相关,且这种关联在GFR较低的受试者中最为显著。